NCI researchers develop approach that could help supercharge T-cell therapies against solid tumors

 Researchers at the National Cancer Institute (NCI) have recently presented findings on ways to improve effectiveness of T-cell immunotherapy treatment (namely CAR T-cell therapy) against solid tumours.   According to laboratory studies, "CAR and TCR T cells modified to express the cytokines IL-15 and IL-21 on their surface killed far more cancer cells than T cells carrying just one of these cytokines or neither of them."  This approach is a more targeted means of delivering the cytokines, thereby lessening severe or fatal side effects. 

Click here to learn more about the study, including listening to an audio soundbite and reading the radio transcript.